Summary
Background Increasing the availability of antigen rapid diagnostic tests (Ag-RDTs) in low- and middle-income countries (LMICs) is key to alleviating global SARS-CoV-2 testing inequity (median testing rate in December 2021-March 2022 when the Omicron variant was spreading in multiple countries; high-income countries=600 tests/100,000 people/day; LMICs=14 tests/ 100,000 people/day). However, target testing levels and effectiveness of asymptomatic community screening to impact SARS-CoV-2 transmission in LMICs are unclear.
Methods We used PATAT, an LMIC-focused agent-based model to simulate COVID-19 epidemics, varying the amount of Ag-RDTs available for symptomatic testing at healthcare facilities and asymptomatic community testing in different social settings. We assumed that testing was a function of access to healthcare facilities and availability of Ag-RDTs. We explicitly modelled symptomatic testing demand from non-SARS-CoV-2 infected individuals and measured impact based on the number of infections averted due to test-and-isolate.
Findings Testing symptomatic individuals yields greater benefits than any asymptomatic community testing strategy until most symptomatic individuals who sought testing have been tested. Meeting symptomatic testing demand likely requires ∼200-400 tests/100,000 people/day on average as symptomatic testing demand is highly influenced by non-SARS-CoV-2 infected individuals. After symptomatic testing demand is satisfied, excess tests to proactively screen for asymptomatic infections among household members yields the largest additional infections averted.
Interpretation Testing strategies aimed at reducing transmission should prioritize symptomatic testing and incentivizing test-positive individuals to adhere to isolation to maximize effectiveness.
Funding European Research Council, the Rockefeller Foundation, and the Governments of Germany, Canada, UK, Australia, Norway, Saudi Arabia, Kuwait, Netherlands and Portugal.
Evidence before this study SARS-CoV-2 transmission can be reduced by test-trace-and-isolate strategies. However, large gaps in global COVID-19 testing equity exist: only ∼20% of tests administered globally as of May 2022 (https://www.finddx.org/covid-19/test-tracker/) were performed in low- and middle-income countries (LMICs) where half the world’s population reside. To narrow the equity gap, expanded access to SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs) in low-resource settings has been prioritized, with the diagnostics pillar of the global Access to COVID-19 Tools (ACT)-Accelerator setting a target testing rate of 100 tests per 100,000 persons per day (/100k/day). Community testing to detect asymptomatic infected individuals has also been proposed to be a key component in bridging the equity gap. We searched PubMed and Google Scholar using combinations of search terms (i.e. “SARS-CoV-2”, “COVID-19”, “diagnostic”, “testing”, “rapid diagnostic tests”, “lateral flow tests”, “Ag-RDT”, “LMIC”) and critically reviewed publications and preprints on how scaling up testing availability using Ag-RDTs and implementing community testing programs alongside healthcare facility-based symptomatic testing would impact community transmissions in LMICs. There is currently no robust quantitative evidence on the strategies or amount of testing needed to reduce community transmission of SARS-CoV-2.
Added value of this study To our knowledge, this is the first study that critically assessed the minimum COVID-19 testing targets set by the ACT-Accelerator in LMICs. This is also the first study that estimated the reduction in secondary SARS-CoV-2 transmissions in LMICs given varying levels of Ag-RDT availability and testing strategies, including the implementation of asymptomatic community testing across different social settings (e.g. households, schools, formal workplaces and regular mass gatherings such as religious gatherings). In doing so, this is the first robust evidence-base on the utility of using Ag-RDTs to scale-up testing-for-mitigation strategies in LMICs.
Implications of all the available evidence Our model showed that testing of symptomatic individuals yields greater reduction in transmissions than any asymptomatic community testing program. Asymptomatic community testing will only support reduced infections after prioritizing available tests for symptomatic individuals who sought testing. The current minimum COVID-19 testing rate target of 100 tests/100k/day can modestly reduce transmissions in LMICs but substantially larger volumes of tests are needed to saturate symptomatic testing demand or effectively implement community testing.
Competing Interest Statement
J.A.S., A.T., N.H., E.H. and B.E.N. were employed by FIND, the global alliance for diagnostics.
Funding Statement
A.X.H. and C.A.R. were supported by ERC NaviFlu (No. 818353). C.A.R. was also supported by NIH R01 (5R01AI132362-04) and an NWO Vici Award (09150182010027).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant to the study are included in the Article, the Supplementary Appendix and the GitHub repository (https://github.com/AMC-LAEB/PATAT-sim). The PATAT model source code can also be found in the GitHub repository (https://github.com/AMC-LAEB/PATAT-sim).